A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

NCT02662634 | Withdrawn Phase 2

• 1 other identifier: AGS-003-024
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.

Conditions

Non-small Cell Lung Cancer (NSCLC)

Keywords

NSCLC; resectable; non-small cell lung cancer; immunotherapy; autologous; dendritic cell

Outcome Measures

Primary Outcomes (2)

• Safety - Adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V4.03

  Safety of AGS-003-LNG for subjects who receive 1 or more doses of AGS-003-LNG in combination with standard platinum-doublet chemotherapy with or without radiation. Adverse events will be collected per CTCAE V4.03.

  2 Years

• Immunogenicity - Generation of Cluster of Differentiation-8 (CD8)+ Cluster of Differentiation (CD28)+ memory T-cells

  Generation of CD8+CD28+ memory T-cells against tumor associated antigens in subject receiving 5 or more doses of AGS-003-LNG.

  After 5th dose of AGS-003-LNG. Within 6 months.

Secondary Outcomes (4)

• Efficacy - Overall survival

  2 Years

• Efficacy - Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

  2 Years

• Efficacy - Objective response rate. The number of patients with a Complete Response or Partial Response.

  2 Years

• Feasibility - Number of patients with a success in the manufacture of AGS-003-LNG.

  1 Month

Study Arms (4)

Sequential, no radiation

EXPERIMENTAL

AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G).

Biological: AGS-003-LNG; Drug: Carboplatin; Drug: Abraxane; Drug: Alimta; Drug: Cisplatin; Drug: Taxol; Radiation: Radiation Therapy

Concurrent, no radiation

EXPERIMENTAL

AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy \& radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells. Platinum-doublet chemotherapy can be any of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G).

Biological: AGS-003-LNG; Drug: Carboplatin; Drug: Abraxane; Drug: Alimta; Drug: Cisplatin; Drug: Taxol; Radiation: Radiation Therapy

Sequential, radiation

EXPERIMENTAL

AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G). Radiation therapy per PI

Biological: AGS-003-LNG; Drug: Carboplatin; Drug: Abraxane; Drug: Alimta; Drug: Cisplatin; Drug: Taxol; Radiation: Radiation Therapy

Concurrent, radiation

EXPERIMENTAL

AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy \& radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells. Platinum-doublet chemotherapy choice of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G). Radiation therapy per PI.

Biological: AGS-003-LNG; Drug: Carboplatin; Drug: Abraxane; Drug: Alimta; Drug: Cisplatin; Drug: Taxol; Radiation: Radiation Therapy

Interventions

AGS-003-LNG BIOLOGICAL

autologous dendritic cell immunotherapy

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Carboplatin DRUG

Carboplatin is an anticancer drug ("antineoplastic" or "cytotoxic") chemotherapy drug. Carboplatin is classified as an "alkylating agent."

Also known as: Paraplatin

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Abraxane DRUG

Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.

Also known as: Protein-bound paclitaxel, nano-particle albumin-bound paclitaxel, nab-paclitaxel

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Alimta DRUG

By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell

Also known as: Pemetrexed

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Cisplatin DRUG

Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis

Also known as: Cisplatinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum(II)

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Taxol DRUG

Mechanism of action involves interference with the normal breakdown of microtubules during cell division.

Also known as: Paclitaxel

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Radiation Therapy RADIATION

Causes DNA strand breaks.

Concurrent, no radiation; Concurrent, radiation; Sequential, no radiation; Sequential, radiation

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 19 years.
• Newly diagnosed non-small cell lung cancer indicated for routine lobectomy, mediastinoscopy, wedge resection, thoracotomy or Video-assisted thoracoscopic surgery (VATS) procedures with tumor collection.
• Stage III (T1-3, N1-2, M0) of any histology.
• Scheduled for routine lobectomy, mediastinoscopy, wedge resection, thoracotomy or VATS procedures.
• Signed and dated informed consent document for study participation.
• After tumor collection, potential subjects must meet all the following criteria to be enrolled in study treatment:
• Successful RNA isolation and amplification from tumor sample (as determined by Argos).
• Karnofsky performance status (KPS) score of 80-100.
• Life expectancy of six months or greater.
• NSCLC of any histology.
• Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
• Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug.
• Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study.
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
• Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment.

You may not qualify if:

• Active autoimmune disease or condition requiring chronic immunosuppressive therapy
• Any clinically significant condition that prohibits the initiation of standard of care.
• Malignancies within the prior three years, except for:
• treated in situ carcinomas or non-melanoma skin cancer.
• adequately treated early stage breast cancer.
• superficial bladder cancer.
• non-metastatic prostate cancer with a normal prostate-specific antigen (PSA) level.
• History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease.
• Clinically significant disorders or conditions including
• cardiovascular system.
• renal system.
• hepatic organ system.
• coagulation disorders.
• Clinically significant infections, including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C.
• Pregnant or breastfeeding.

Sponsors & Collaborators

• GU Research Network, LLC: lead

Study Sites (1)

Cancer Research Network of Nebraska / Oncology Associates

Omaha, Nebraska, 68118, United States

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Carboplatin; Albumin-Bound Paclitaxel; 130-nm albumin-bound paclitaxel; Pemetrexed; Cisplatin; Paclitaxel; Radiotherapy

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes; Albumins; Proteins; Amino Acids, Peptides, and Proteins; Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Dicarboxylic; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Therapeutics

Study Officials

• Luke T Nordquist, MD

  Cancer Research Network of Nebraska

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 12, 2016
• First Posted: January 25, 2016
• Study Start: March 1, 2016
• Primary Completion: March 1, 2018
• Study Completion: March 1, 2018
• Last Updated: March 18, 2022

Record last verified: 2016-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)